{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T19:26:15Z","timestamp":1779305175839,"version":"3.51.4"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Recently, the ASCO and ESMO guidelines on salivary gland carcinomas (SGCs) have been released. However, several crucial points lack strong recommendations due to low or intermediate quality of evidence. To better address these \u201cgrey zones\u201d in the guidelines, we conducted a survey among the European Organization for Research and Treatment of Cancer (EORTC) Head and Neck Cancer Group (HNCG) members on behalf of the EORTC young and early career investigators.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>The survey included 29 questions addressing diagnostic and therapeutic issues related to SGC patients and was shared among 539 members of the EORTC HNCG. Responses were collected from December 2022 to March 2023. The primary aim was to evaluate the decision-making criteria guiding physicians in areas with low evidence in SGC guidelines.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>With a response rate of 19%, the survey received input from 102 respondents, mainly medical oncologists (45%). Among those with pathological high-risk features, 35% and 30% of respondents opted for chemoradiotherapy (CRT) in the definitive and adjuvant settings, respectively. For patients with R0 resection of highly aggressive SGC at the pT1\u20132 stage, 37% proposed a close follow-up, while 38% proposed adjuvant lymph-node field RT. In cases of pT3\u20134 stage, 48% proposed adjuvant lymph-node field RT in all cases, and 44% proposed it based only on risk factors. The most important factors guiding the decision to give adjuvant RT after salvage surgery for locoregional relapse include previous radiotherapy, margin status, and the presence of extranodal extension. When faced with combined positivity to HER2 and AR, responses regarding the choice of first-line palliative treatment were heterogeneous.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>International guidelines lack strong recommendations in several fields of SGC diagnosis and treatment due to insufficient high-quality data, resulting in heterogeneity in physicians\u2019 treatment decision (e.g., adjuvant lymph-node field RT and their low concordance with guidelines, such as the use of concomitant CRT). The survey demonstrated the need for prospective clinical trial data to address these gaps in the future.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2024.1416097","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T06:10:16Z","timestamp":1731046216000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Diving into hot topics of salivary gland carcinoma management\u2014an EORTC young and early career investigator survey"],"prefix":"10.3389","volume":"14","author":[{"given":"Luigi","family":"Lorini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Ronchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daan","family":"Nevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konrad","family":"Klinghammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ester","family":"Orlandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Bossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petr","family":"Szturz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,8]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: An overview","volume-title":"Int J Cancer","author":"Ferlay","year":"2021"},{"key":"B2","doi-asserted-by":"publisher","first-page":"JCO.21.00449","DOI":"10.1200\/JCO.21.00449","article-title":"Management of salivary gland Malignancy: ASCO guideline","author":"Geiger","year":"2021","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"100602","DOI":"10.1016\/j.esmoop.2022.100602","article-title":"Salivary gland cancer: ESMO\u2013European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"7","author":"Van Herpen","year":"2022","journal-title":"ESMO Open"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/lary.v127.9","article-title":"Patterns of care and survival of adjuvant radiation for major salivary adenoid cystic carcinoma","volume":"127","author":"Lee","year":"2017","journal-title":"Laryngoscope"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/lary.v123.11","article-title":"Long-term outcomes of surgery followed by radiation therapy for minor salivary gland carcinomas","volume":"123","author":"Zeidan","year":"2013","journal-title":"Laryngoscope"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2015.05.005","article-title":"Outcomes and prognostic factors in modern era management of major salivary gland cancer","volume":"51","author":"Jegadeesh","year":"2015","journal-title":"Oral Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/hed.10400","article-title":"Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group","volume":"26","author":"Terhaard","year":"2004","journal-title":"Head Neck"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1177\/0194599817717661","article-title":"Impact of adjuvant radiotherapy for Malignant salivary gland tumors","volume":"157","author":"Safdieh","year":"2017","journal-title":"Otolaryngol Neck Surg"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1001\/archoto.2011.158","article-title":"Adjuvant radiation therapy for high-grade and\/or locally advanced major salivary gland tumors","volume":"137","author":"Mahmood","year":"2011","journal-title":"Arch Otolaryngol Neck Surg"},{"key":"B10","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1634\/theoncologist.2019-0841","article-title":"The benefits of adjuvant trastuzumab for HER-2-positive salivary gland cancers","volume":"25","author":"Hanna","year":"2020","journal-title":"Oncologist"},{"key":"B11","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1634\/theoncologist.2012-0369","article-title":"Trastuzumab for the treatment of salivary duct carcinoma","volume":"18","author":"Limaye","year":"2013","journal-title":"Oncologist"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1264287","article-title":"Current management and future challenges in salivary glands cancer","volume":"13","author":"Locati","year":"2023","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx399","article-title":"Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies","volume":"28","author":"Ross","year":"2017","journal-title":"Ann Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0637","article-title":"Comprehensive molecular characterization of salivary duct carcinoma reveals actionable targets and similarity to apocrine breast cancer","volume":"22","author":"Dalin","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1096068","article-title":"HER2 status in recurrent\/metastatic androgen receptor overexpressing salivary gland carcinoma patients","volume":"12","author":"Cavalieri","year":"2023","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1107134","article-title":"Targeted treatment in a case series of AR+, HRAS\/PIK3CA co-mutated salivary duct carcinoma","volume":"13","author":"Rieke","year":"2023","journal-title":"Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/hed.24984","article-title":"Adjuvant therapy in major salivary gland cancers: Analysis of 8580 patients in the National Cancer Database","volume":"40","author":"Cheraghlou","year":"2018","journal-title":"Head Neck"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1177\/0194599816636812","article-title":"Salivary duct carcinoma of the parotid: outcomes with a contemporary multidisciplinary treatment approach","volume":"154","author":"Mifsud","year":"2016","journal-title":"Otolaryngol Neck Surg"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000386","article-title":"Concurrent chemoradiotherapy in the adjuvant treatment of high-risk primary salivary gland Malignancies","volume":"41","author":"Gebhardt","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"B20","unstructured":""},{"key":"B21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ejca.2018.12.035","article-title":"Adjuvant androgen deprivation therapy for poor-risk, androgen receptor\u2013positive salivary duct carcinoma","volume":"110","author":"Van Boxtel","year":"2019","journal-title":"Eur J Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/hed.21831","article-title":"Concurrent chemoradiotherapy for locoregionally advanced salivary gland Malignancies","volume":"34","author":"Rosenberg","year":"2012","journal-title":"Head Neck"},{"key":"B23","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3322\/caac.21807","article-title":"The evolving landscape of salivary gland tumors","volume":"73","author":"Steuer","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.anorl.2023.11.006","article-title":"Radiotherapy for salivary gland cancer: REFCOR recommendations by the formal consensus method","volume":"141","author":"Thariat","year":"2024","journal-title":"Eur Ann Otorhinolaryngol Head Neck Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.011","article-title":"Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS\u2013ESMO\u2013ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Machiels","year":"2020","journal-title":"Ann Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/hed.10380","article-title":"Radiotherapy alone or combined with surgery for adenoid cystic carcinoma of the head and neck","volume":"26","author":"Mendenhall","year":"2004","journal-title":"Head Neck"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2018.08.018","article-title":"Guidelines for clinical target volume definition for perineural spread of major salivary gland cancers","volume":"30","author":"Armstrong","year":"2018","journal-title":"Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"14584","DOI":"10.1038\/s41598-017-14607-2","article-title":"Targeting androgen receptor in treating HER2 positive breast cancer","volume":"7","author":"He","year":"2017","journal-title":"Sci Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/annonc\/annonc1594","article-title":"Phase II study of trastuzumab deruxtecan in patients with HER2-positive recurrent\/metastatic salivary gland cancer: Results from the MYTHOS trial","volume":"35","author":"Kinoshita","year":"2024","journal-title":"Ann Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/annonc\/annonc1623","article-title":"A randomised phase II study to evaluate the efficacy and safety of androgen deprivation therapy (ADT) vs chemotherapy (CT) gin patients with recurrent and\/or metastatic, androgen receptor (AR) expressing, salivary gland cancers","volume":"35","author":"Licitra","year":"2024","journal-title":"Ann Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1416097\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T06:10:18Z","timestamp":1731046218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1416097\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":30,"alternative-id":["10.3389\/fonc.2024.1416097"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1416097","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,8]]},"article-number":"1416097"}}